The injectables market is largely unregulated anyone can call themselves an aesthetic clinic
Evernorth benefit program - Through direct negotiations with manufacturers, this program ensures patients' monthly costs won't exceed $200, potentially saving up to $3,600 annually compared to direct purchasing
One in eight (13%) American adults have tried the medications, and about 6% are currently taking them
BCRF researchers are actively investigating and reporting data on how the drugs help patients and thrivers
to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week
